Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.20    3.40 (2.23%)
Bid:
156.00
Ask:
156.40
Spread: 0.40 (0.256%)
Market Cap: £893.96m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM / Interim Management Statement

22 Apr 2015 07:00

ELEMENTIS PLC - AGM / Interim Management Statement

ELEMENTIS PLC - AGM / Interim Management Statement

PR Newswire

London, April 21

22 April 2015 Elementis plc - AGM / Interim Management Statement Elementis plc (ELM.L, the "Company" or the "Group"), the Global SpecialtyChemicals Company, today issues its Interim Management Statement for the threemonths ended 31 March 2015. Commenting on the Company's performance Group Chief Executive, David Dutro,said: "Despite subdued global economic activity,the Elementis team hasdelivered encouraging results in the first quarter of 2015 and we remainconfident in the Group's prospects for the coming year. Moving forward ourstrategy is clear and focused on delivering long-term shareholder value. Weremain resolute in our commitment to outperform our competitors by providinginnovative products and solutions that make our customers more successful. Wehave continued to invest in the future growth of our Specialty Productsbusiness andalthough we are currently in the phase of absorbing the additionalrelated costs,these investmentsare the building blocks of an exciting future". CurrencyConsistent with the Group's Final Results statement in February this year,currency movements reduced Group sales for the first quarter by 5 per centcompared to the same period last year, however, operating profit was impactedby less than 1 per cent, assisted by the Group's hedging programme. In order toprovide a clearer understanding of the Group's underlying performance thefollowing business commentaries focus on constant currency sales ("CC sales"). In Specialty Products, CC sales in the first quarter were 3 per cent higherthan the same period last year and operating margins improved by 50 basispoints, assisted by currency movements. * In coatings additives, CC sales in North America were 4 per cent higher than the previous year, with good growth in decorative coatings as a result of new innovative products from the recently commissioned facility in New Martinsville. Sales in Latin America were 9 per cent higher as the business continued to successfully expand sales outside of Brazil. Sales in Asia Pacific were 5 per cent higher, benefiting from ongoing market share gains in China and good progress in other countries. In Europe, despite relatively subdued economic activity, sales grew by 5 per cent due to new product launches in decorative applications and market share gains. * In personal care, CC sales were 6 per cent higher than the same period last year with good growth in North America, Asia Pacific and Latin America. The business team continues to successfully expand the business both geographically and through new product introductions. * As anticipated, CC sales in oilfield were 13 per cent lower than the first quarter of 2014, as lower oil prices impacted on drilling activity across most of the customer base. In Chromium, there was no significant currency translation impact on sales andoperating profit. Sales volumes in the first quarter were 7 per cent lower thanthe same period last year as demand for refractory grade chrome oxide, whichwas particularly strong in 2014, returned to more normal levels following thecompletion of a number of significant customer projects. Otherwise sales inleather tanning and timber treatment continued to show good growth. Fixed costsin the period benefited from plant optimisation activities and the positiveresolution of some legacy issues. While markets outside of North Americacontinue to be challenging, management expects a full year result that is inline with the business's stated strategy of "stable earnings and cash flow". The Group's balance sheet remains strong and is expected to be in a net cashposition at the end of the year which, under our current special dividendpolicy, will continue to provide shareholders with attractive returns. ENDS Enquiries: Elementis + 44 (0) 207 408 9300David Dutro, Chief ExecutiveBrian Taylorson, Finance Director FTI Consulting + 44 (0) 203 727 1000Deborah ScottMatthew Cole
Date   Source Headline
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.